Aptus Biosciences

Aptus Biosciences is a private, pre-revenue diagnostics company focused on reinventing aptamer technology for clinical applications. The company is developing a platform of chemically modified DNA aptamers designed as high-specificity, high-affinity reagents for detecting disease biomarkers. Its initial pipeline targets major therapeutic areas including neurology, oncology, cardiology, and infectious diseases, with the goal of enabling earlier and more accurate diagnosis. As an early-stage venture, Aptus is likely seeking partnerships and investment to advance its programs from platform development into validated diagnostic assays.

Proprietary platform for developing chemically modified DNA aptamers, designed to enhance stability, affinity, and specificity for use as diagnostic affinity reagents in complex biological samples.

Aptus competes with the dominant antibody industry, other aptamer-focused companies (e.g., SomaLogic, Aptamer Group), and emerging affinity reagent technologies. Success requires demonstrating clear advantages in cost, stability, or performance over these established and emerging alternatives.